ACTU Latest Press Releases

-- June 9, 2026 --

Actuate Therapeutics' Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma Globe Newswire 7:45 AM

-- June 1, 2026 --

Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer Globe Newswire 7:00 AM

-- May 11, 2026 --

Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program Globe Newswire 7:00 AM

-- May 6, 2026 --

Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors Globe Newswire 8:45 AM

-- April 14, 2026 --

Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Globe Newswire 8:45 AM

-- March 24, 2026 --

Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers ACCESS Newswire 7:00 AM

-- March 9, 2026 --

Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors Globe Newswire 8:45 AM

-- March 4, 2026 --

Actuate Therapeutics to Present at The Citizens Life Sciences Conference Globe Newswire 5:00 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software